1. Home
  2. RANI vs MTVA Comparison

RANI vs MTVA Comparison

Compare RANI & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RANI
  • MTVA
  • Stock Information
  • Founded
  • RANI 2012
  • MTVA 2014
  • Country
  • RANI United States
  • MTVA United States
  • Employees
  • RANI N/A
  • MTVA N/A
  • Industry
  • RANI Medicinal Chemicals and Botanical Products
  • MTVA
  • Sector
  • RANI Health Care
  • MTVA
  • Exchange
  • RANI Nasdaq
  • MTVA NYSE
  • Market Cap
  • RANI 17.0M
  • MTVA 14.3M
  • IPO Year
  • RANI 2021
  • MTVA N/A
  • Fundamental
  • Price
  • RANI $0.53
  • MTVA $0.71
  • Analyst Decision
  • RANI Strong Buy
  • MTVA Strong Buy
  • Analyst Count
  • RANI 4
  • MTVA 2
  • Target Price
  • RANI $7.75
  • MTVA $7.50
  • AVG Volume (30 Days)
  • RANI 4.6M
  • MTVA 64.8K
  • Earning Date
  • RANI 08-05-2025
  • MTVA 08-13-2025
  • Dividend Yield
  • RANI N/A
  • MTVA N/A
  • EPS Growth
  • RANI N/A
  • MTVA N/A
  • EPS
  • RANI N/A
  • MTVA N/A
  • Revenue
  • RANI $1,200,000.00
  • MTVA N/A
  • Revenue This Year
  • RANI N/A
  • MTVA N/A
  • Revenue Next Year
  • RANI N/A
  • MTVA N/A
  • P/E Ratio
  • RANI N/A
  • MTVA N/A
  • Revenue Growth
  • RANI N/A
  • MTVA N/A
  • 52 Week Low
  • RANI $0.39
  • MTVA $0.60
  • 52 Week High
  • RANI $3.75
  • MTVA $4.36
  • Technical
  • Relative Strength Index (RSI)
  • RANI 50.55
  • MTVA N/A
  • Support Level
  • RANI $0.40
  • MTVA N/A
  • Resistance Level
  • RANI $0.45
  • MTVA N/A
  • Average True Range (ATR)
  • RANI 0.07
  • MTVA 0.00
  • MACD
  • RANI 0.00
  • MTVA 0.00
  • Stochastic Oscillator
  • RANI 30.27
  • MTVA 0.00

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

About MTVA METAVIA INC

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.

Share on Social Networks: